← Back to Screener
Adicet Bio, Inc. Common Stock (ACET)
Price$8.67
Favorite Metrics
Price vs S&P 500 (26W)-55.65%
Price vs S&P 500 (4W)9.29%
Market Capitalization$78.88M
All Metrics
Book Value / Share (Quarterly)$16.61
P/TBV (Annual)2.20x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-10.12
Price vs S&P 500 (YTD)-6.51%
Net Profit Margin (TTM)-93.15%
EPS (TTM)$-19.59
10-Day Avg Trading Volume0.21M
EPS Excl Extra (TTM)$-19.59
EPS (Annual)$-1.33
ROI (Annual)-62.70%
Net Profit Margin (5Y Avg)-548.85%
Cash / Share (Quarterly)$16.54
ROA (Last FY)-53.13%
EBITD / Share (TTM)$-19.39
ROE (5Y Avg)-44.86%
Operating Margin (TTM)-91.40%
Cash Flow / Share (Annual)$-10.12
P/B Ratio0.50x
P/B Ratio (Quarterly)0.51x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)1.06x
Net Interest Coverage (TTM)-689.22x
ROA (TTM)-68.00%
EPS Incl Extra (Annual)$-1.33
Current Ratio (Annual)7.47x
Quick Ratio (Quarterly)7.38x
3-Month Avg Trading Volume0.17M
52-Week Price Return-10.07%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$7.63
P/S Ratio (Annual)3.16x
Asset Turnover (Annual)0.08x
52-Week High$17.44
Operating Margin (5Y Avg)-566.93%
EPS Excl Extra (Annual)$-1.33
CapEx CAGR (5Y)11.91%
Tangible BV CAGR (5Y)40.58%
26-Week Price Return-46.90%
Quick Ratio (Annual)7.38x
13-Week Price Return-0.84%
Total Debt / Equity (Annual)0.01x
Current Ratio (Quarterly)7.47x
Enterprise Value$40.956
Asset Turnover (TTM)0.13x
Book Value / Share Growth (5Y)24.40%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-279.27%
Cash / Share (Annual)$16.54
3-Month Return Std Dev72.04%
Net Income / Employee (TTM)$-1
ROE (Last FY)-62.70%
EPS Basic Excl Extra (Annual)$-1.33
Receivables Turnover (TTM)249.90x
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$-19.59
Receivables Turnover (Annual)270.16x
ROI (TTM)-82.67%
P/S Ratio (TTM)2.04x
Pretax Margin (5Y Avg)-554.32%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$7.63
Price vs S&P 500 (52W)-45.16%
Year-to-Date Return-2.38%
5-Day Price Return29.45%
EPS Normalized (Annual)$-1.33
ROA (5Y Avg)-37.04%
Net Profit Margin (Annual)-279.27%
Month-to-Date Return20.70%
Cash Flow / Share (TTM)$-3.21
EBITD / Share (Annual)$-1.26
Operating Margin (Annual)-290.32%
ROI (5Y Avg)-44.86%
EPS Basic Excl Extra (TTM)$-19.59
P/TBV (Quarterly)2.20x
P/B Ratio (Annual)0.51x
Pretax Margin (TTM)-93.36%
Book Value / Share (Annual)$16.61
Price vs S&P 500 (13W)-3.71%
Beta1.59x
Revenue / Share (TTM)$0.00
ROE (TTM)-82.96%
52-Week Low$6.01
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.31
4.31
4.31
4.31
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ACETAdicet Bio, Inc. Common Stock | 2.04x | — | — | — | $8.67 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Adicet Bio is a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases. ADI-001, its lead candidate, is a CD20-targeting CAR T cell therapy in development for relapsed or refractory B cell lymphomas and autoimmune indications. The company's pipeline also includes ADI-270, a preclinical CAR T program targeting CD70 for renal cell carcinoma and other solid tumors.